Loading clinical trials...
Loading clinical trials...
A Phase I Dose Finding Study of the Pan-DAC Inhibitor Panobinostat (LBH589) in Combination With Etoposide and Cisplatin in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer - An ICORG In-House Study
Conditions
Interventions
cisplatin
etoposide phosphate
+3 more
Start Date
November 1, 2009
Primary Completion Date
October 1, 2010
Last Updated
December 31, 2014
NCT07336732
NCT07486219
NCT07485114
NCT06498635
NCT06066138
NCT07190248
Lead Sponsor
Cancer Trials Ireland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions